BMS Reports EXCALIBER-RRMM Results for ZENBEXUS
PRINCETON, N.J. — September 26, 2026 Bristol Myers Squibb announced the first presentation of results from the pivotal Phase...
Bristol Myers Squibb
Advertisement
Bristol Myers Squibb Reports Durable Sotyktu Results in PsA
PRINCETON, N.J. — September 17, 2026 Bristol Myers Squibb announced positive two-year results from the Phase 3 POETYK PsA-2...
BMS Reports Positive Phase 2 CAR T Cell Trial Results
Princeton, New Jersey, U.S., September 8, 2026 Bristol Myers Squibb (BMS) has announced positive topline results from the registrational...
Cytokinetics Highlights Phase 3 Aficamten Data at ESC
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...
Bristol Myers Squibb Reports Five-Year Camzyos Data
PRINCETON, N.J., August 26, 2026 Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society...
Advertisements
Leads Biolabs Advances Opamtistomig Toward Approval
NANJING, China, August 21, 2026 Nanjing Leads Biolabs Co., Ltd. announced that China’s Center for Drug Evaluation (CDE) under...
Chai Discovery and BMS Advance AI Antibody Discovery
San Francisco, California, August 20, 2026 Chai Discovery has announced a collaboration with Bristol Myers Squibb (BMS) to advance...
Bristol Myers Squibb Expands AI Collaboration with NVIDIA
PRINCETON, N.J., July 20, 2026 Bristol Myers Squibb (BMS) announced a major expansion of its strategic collaboration with NVIDIA...
Tempus AI and Bristol Myers Squibb Expand AI Clinical Trial Partnership
CHICAGO, Illinois, May 2026 Tempus AI announced an expanded strategic collaboration with Bristol Myers Squibb aimed at improving the...
Tigerlily Foundation and BMS Expand Clinical Trial Access
Washington, D.C. – May 15, 2026 Tigerlily Foundation announced a new collaboration with Bristol Myers Squibb focused on improving...
Advertisement
